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In large-vessel vasculitides, inflammatory infiltrates may cause thickening of the involved
arterial vessel wall leading to progressive stenosis and occlusion. Dilatation, aneurysm for-
mation, and thrombosis may also ensue. Activated macrophages and T lymphocytes are
fundamental elements in vascular inflammation. The amount and density of the inflam-
matory infiltrate is directly linked to local disease activity. Additionally, patients with
autoimmune disorders have an increased cardiovascular (CV) risk compared with age-
matched healthy individuals as a consequence of accelerated atherosclerosis. Molecular
imaging techniques targeting activated macrophages, neovascularization, or increased cel-
lular metabolic activity can represent effective means of non-invasive detection of vascular
inflammation. In the present review, novel non-invasive imaging tools that have been
successfully tested in humans will be presented. These include contrast-enhanced ultra-
sonography, which allows detection of neovessels within the wall of inflamed arteries;
contrast-enhanced CV magnetic resonance that can detect increased thickness of the arte-
rial wall, usually associated with edema, or mural enhancement usingT2 and post-contrast
T1-weighted sequences, respectively; and positron emission tomography associated with
radio-tracers such as [18F]-fluorodeoxyglucose and the new [11C]-PK11195 in combina-
tion with computed tomography angiography to detect activated macrophages within the
vessel wall. Imaging techniques are useful in the diagnostic work-up of large- and medium-
vessel vasculitides, to monitor disease activity and the response to treatments. Finally,
molecular imaging targets can provide new clues about the pathogenesis and evolution of
immune-mediated disorders involving arterial vessels.
Keywords: vasculitis, non-invasive imaging, contrast-enhanced ultrasound, vascular inflammation, positron emis-
sion tomography, cardiovascular magnetic resonance
INTRODUCTION
Vasculitides are conditions defined by the presence of inflamma-
tion of the vessel wall, with progressive alteration of the lumen,
including lumen stenosis, occlusion, or even aneurysmal dilation.
They can be broadly divided into infectious vasculitides, char-
acterized by direct invasion of pathogens in the vessel wall and
non-infectious vasculitides. The latter, also known as primary vas-
culitides, encompass a heterogeneous group of immune-mediated
disorders, classified, according to the size of vessels that are pre-
dominantly involved, into small-, medium-, and large-vessel vas-
culitides (LVV) (1). The diagnosis of small and medium vessels
vasculitis is generally based on clinical findings, serological mark-
ers, and histological evaluation (2). LVV include giant cell arteritis
(GCA), Takayasu arteritis (TAK), primary central nervous system
vasculitis (PCNSV), and chronic periaortitis (CP) (3). The most
common LVVs are GCA and TAK in which the aorta and its main
branches are generally involved. GCA occurs more frequently in
older adults, showing a predilection for the temporal artery and
other extracranial vessels (4). Clinical manifestation of this disease
ranges from ischemic symptoms and signs (such as jaws claudi-
cation) to aneurysmal rupture (4, 5). TAK is more prevalent in
adolescent girls and young women, with a strong predilection for
the aortic arch and its branches, in particular the subclavian arter-
ies (up to 98%) and common carotid, although also pulmonary
and coronary arteries (<10%) may be involved. The involvement
of the major branches of the aorta is much more marked at their
origin than distally, leading to clinical manifestations that ranges
from arm claudication to myocardial infarction. Different classifi-
cation criteria for LVV have been defined, and all of them are based
upon clinical presentation, evidence of inflammation, and vascular
abnormalities (6–8). However, they have proven largely unsatisfac-
tory for diagnostic purposes (9, 10), frequently leading to delayed
diagnosis (11). Even once the diagnosis is established, accurate
monitoring of disease activity and response to therapy is not an
easy task (5). Extensive clinical evaluation of the arterial tree is cur-
rently recommended (12), and imaging plays a major role in this
setting. In vivo detection of inflammation within affected blood
vessels may provide a reliable tool to assess disease activity, leading
to better clinical management of the patient. Although imaging
techniques are particularly useful to diagnose and monitor LVV,
they can also play a role in the work-up of medium-vessel vas-
culitides, classically represented by polyarteritis nodosa (PAN) in
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Table 1 | Features of main non-invasive imaging technique for vascular
imaging.
Imaging technique Form of energy Spatial
resolution
(mm)
Availability
Ultrasonography High frequency sound
waves
0.1-1 Widespread
CT X rays 0.3-1 Widespread
MRI Radiofrequency
waves
0.2 Large centers
PET Photons annihilation 4-6 Large centers
PET: positron emission tomography; CT: computed tomography; MRI: magnetic
resonance imaging.
adults and Kawasaki disease (KD) in children (13, 14). In contrast,
current imaging techniques are unable to visualize small vessels,
thus we will focus on the role of imaging studies in diagnosing and
monitoring LVV, including some applications in medium-vessel
vasculitides and autoimmune systemic disorders with potential
vascular involvement such as Behcet’s disease.
Inflammation of the vascular wall is characterized by different
pathological changes, such as edema, vasa vasorum activation and
proliferation (15, 16), alteration of endothelial homeostatic func-
tion, and immune cells infiltration (4, 17, 18), ultimately leading
to anatomical remodeling with consequent functional alteration.
Knowledge of the biological basis of these processes has led to
the development of imaging strategies aimed at identifying them
in vivo, mainly with the development of probes directed to key
molecular targets (19). Imaging techniques allowing for molecular
imaging include ultrasonography, positron emission tomography
(PET), most often associated with computed tomography (CT),
and magnetic resonance imaging (MRI), all of which will be dis-
cussed in this review. Table 1 summarizes the main features of
the imaging techniques used to study patients with vasculitides.
Furthermore, inflammation of arterial vessels is a fundamental
pathogenetic element in atherosclerosis and associated clinical
manifestations. Compelling evidence of the link between athero-
genesis and inflammation has built over the last decades, leading to
the current hypothesis that atherosclerosis is not merely a disease
due to passive lipid accumulation in the vascular wall but an active,
immune-driven process (17, 18). Not surprisingly, many diseases
associated with systemic inflammation due to immune alterations
are associated with increased risk of cardiovascular (CV) morbid-
ity and mortality due to atherosclerosis (20, 21) that cannot be
fully explained by traditional CV risk factors, suggesting a role for
immune activation (22). Therefore, characterization of inflamma-
tion within atherosclerotic plaques by means of molecular imaging
may identify patients at risk for disease progression or acute clinical
manifestations (23, 24).
ULTRASOUND
Ultrasound imaging is widely available, inexpensive, and repeat-
able and does not involve the use of ionizing radiation. It is
generally performed by an experienced sonographer using high-
quality Doppler ultrasound equipment and linear probes> 8 MHz
(25, 26). Examination typically comprises B-mode ultrasonog-
raphy, which depicts anatomy using a gray scale, and Duplex
ultrasound, which combines color Doppler ultrasound and pulsed
Doppler ultrasound to display information about blood flow and
to estimate blood flow velocities (26). The main limitation of
ultrasound imaging is that it cannot depict structures below bone
or air. For this reason, it does not provide reliable information
about the thoracic aorta, unless performed via a transesophageal
approach. In addition, acquisition of ultrasound images is oper-
ator dependent, although studies of vascular ultrasound have
shown high rates of interoperator agreement (27, 28). In the fol-
lowing sections, we will review the main ultrasonographic findings
in blood vessel inflammation, which are summarized in Tables 2
and 3.
COLOR DOPPLER ULTRASOUND
Schmidt et al. pioneered the use of ultrasonography in LVV. They
showed that inflamed temporal arteries in GCA were character-
ized by a dark hypoechoic circumferential wall thickening dubbed
the halo sign, which appeared to be edema of the vessel (29).
The investigators reported a sensitivity of 73% and a specificity
of nearly 100%. Subsequently, temporal artery ultrasonography
has increasingly been used to screen patients with suspected GCA.
An early meta-analysis showed a sensitivity of 69% and a speci-
ficity of 82% for the halo sign using temporal artery biopsy as
the reference standard (30). Subsequent meta-analysis showed a
sensitivity of 69% and a specificity of 91% (31), and a sensitivity
of 69% and a specificity of 89% (32), respectively, when American
College of Rheumatology (ACR) criteria were used as reference
standard. Interestingly, specificity increased to 100% when pres-
ence of the halo sign was bilateral (31). As expected, the quality of
the equipment used to perform the examination as well as oper-
ator experience was shown to affect diagnostic power of the halo
sign (30–32). The halo sign can also be found in inflamed large
vessels, which have been shown to be involved in approximately
one-third of patients affected by GCA (33, 34). Detection of the
halo sign in large vessels further increases ultrasound sensitivity
to nearly 100% (35, 36). The equivalent of the halo sign in TAK is
called the macaroni sign, a circumferential midechoic thickening
of the blood vessel wall (37). Both of these echographic findings
have been shown to fade and disappear after initiation of steroid
therapy during patients follow-up (38–40). Aside from edema,
ultrasound evaluation of the vessel wall may show other vascular
alterations. Evaluation of carotid artery wall thickness, i.e., carotid
artery intima-media thickness (CIMT), in particular has proved a
reliable surrogate measure of atherosclerotic burden and CV risk
in the general population (41). CIMT (Figure 1) was shown to be
significantly increased in patient affected by a variety of rheumatic
diseases: this may represent the result of a multifactorial process
in which age and other traditional CV risk factors (i.e., systolic
blood pressure, low-density lipoprotein (LDL), cholesterol levels,
and body mass index) make a continuous contribution, and inter-
act with inflammation and immunological factors (42, 43). Clear
depiction of blood vessel lumen allows detection of stenosis or
aneurysmal dilation, which appear as alterations in wall profile as
well as flow abnormalities, making ultrasound a valuable tool for
monitoring vasculitides complications (3).
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Table 2 | Summary of main ultrasonographic findings in inflamed blood vessel, together with their pathological correlate and clinical
significance.
Sign Alteration Pathological correlate Clinical significance Vasculitis Reference
Halo sign or Macaroni sign Hypoechoic concentric
thickening of blood
vessel wall
Edema High sensitivity and
specificity for LVV
diagnosis; potential role
for follow-up
GCA (halo sign) and TAK
(macaroni sign)
(29–32,
38–40)
Increased common carotid
artery intima-media
thickness (IMT)
Thickening of common
carotid artery vessel wall
Vascular remodeling
under pathological stimuli
Increased risk for CV
events
All conditions associated
with high CV risk,
including vasculitis
(41–43)
Stenosis, occlusion or
aneurysmal dilation
Reduction (stenosis and
occlusion) or increase in
vessel caliber; flow
alterations
Advanced pathological
remodeling of blood
vessels
Cause of ischemic
symptoms and signs; risk
of aneurysmal rupture;
patient follow-up
All (3, 5)
Adventitial neovessels
with contrast-enhanced
ultrasound (CEUS)
Moving bright spots on
the adventitial layer of
the vessel wall after
microbubbles
administration
Neoangiogenesis due to
inflammation*
May correlate with
vasculitis activity
TAK and GCA (48–50)
*Correlation with neovessel formation has been demonstrated for atherosclerosis. Pathological correlation studies for vasculitides have not yet been performed.
CONTRAST-ENHANCED ULTRASOUND
Several different formulations of ultrasound contrast agents exist.
They share the feature of being micro or nano sized, gas-filled
particles, known as microbubbles, which remain in the vascular
compartment. They generate a hyperechogenic signal because they
resonate, i.e., cyclically expand and contract, or release gas when
insonated at frequencies used by ultrasound imaging systems (44).
When applied to vascular imaging, contrast-enhanced ultrasound
(CEUS) is able to enhance the lumen, improving delineation of
blood vessel wall (45). In addition, microbubbles allow detec-
tion of adventitial neovessels (46), which is a potential marker for
atherosclerotic plaque instability (47). Recently, CEUS has been
proposed as a potentially useful imaging modality in assessing
disease activity in LVV. In early reports by Giordana et al. (48)
and Magnoni et al. (49), carotid CEUS was used to diagnose
TAK and monitor response to treatment. The authors initially
observed circumferential wall thickening in the common carotid
artery with multiple vasa vasorum. After treatment, carotid CEUS
was repeated and showed progressive reduction in vessel wall and
vasa vasorum enhancement, suggesting decrease of inflamma-
tory activity in the carotid artery. CEUS improved definition of
borders of the vascular lesion and demonstrated the presence of
large amount of contrast, visualized by moving bright spots, on
the adventitial side of vascular lesions (Figures 2A,B). The latter
phenomenon was interpreted as a signal coming from neovessels.
More recently, Schinkel et al. (50) confirmed these results in a pilot
study involving seven patients, of which five were affected by TAK
and two by GCA. They showed that CEUS significantly improved
image quality as compared to standard color Doppler ultrasound
and allowed detection of vascularization in carotid vessel wall.
CEUS can be employed for molecular imaging (51, 52); unlike
freely circulating microbubbles used for vascular opacification,
targeted microbubbles are designed to adhere to the endothe-
lium through specific interactions. The adhesion is then detected
as increase in echogenicity, which persists after circulating bub-
bles have been washed away in the site where molecular target is
localized. Examples of targets successfully visualized in preclini-
cal experimental models with molecular targeted CEUS include
leukocyte adhesion molecules including ICAM-1, VCAM-1, and
P-selectin. In the future, this technology will provide the possi-
bility of directly visualizing pathophysiologic events, including
inflammatory changes, occurring in the patient’s blood vessels.
The fact that proliferation of vasa vasorum and intimal neovas-
cularization may play a role in atherosclerosis was clearly shown
by postmortem studies by Barger et al. (53), who showed that ath-
erosclerotic segments of coronary arteries present a rich vascular
network extending from the adventitia to the intima. Atheroscle-
rotic plaque neovascularization may contribute to the progression
of a fibrotic, stable lesion to an unstable lesion at high risk of rup-
ture (47, 54). Visualization of intra-plaque neovascularization may
therefore provide a way to identify high risk, vulnerable plaques.
Detection of blood vessel wall enhancement by CEUS was shown
to correlate well with histological evidence of plaque neovascular-
ization, as defined by presence of CD31 positive cells (46, 55). This
technique may thus have a relevant future role in risk assessment
of atherosclerotic plaques also in patients with immune-mediated
disorders.
TRANSESOPHAGEAL ECHOCARDIOGRAPHY
Transesophageal echocardiography (TEE) is a semi-invasive ultra-
sound imaging technique that allows high-quality evaluation of
the heart and the aortic root. The exam is carried out using
an ultrasonographic transducer mounted on the tip of a mod-
ified steerable gastroscope inserted in the esophagus (56). This
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Table 3 | Summarizes key studies concerned with imaging of inflammation in blood vessels in LVV, and their main results.
Technique Study Number of
patients
Results Reference
Color Doppler ultrasound Ball et al., The British Journal of Surgery,
2010
998 Meta-analysis of 17 studies showing a
sensitivity of 69% and a specificity of
89% for the halo sign in temporal artery
(32)
Arida et al., BMC Muscoloskeletal
Disorders, 2010
504 Meta-analysis of 8 studies showing a
sensitivity of 68% and a specificity of
91% for the halo sign in temporal artery
(31)
Maeda et al., Ultrasound Med Mol, 1991 23 “Macaroni” sign detected carotid artery
involvement in 19 out of 23 patients with
TAK
(37)
Habib et al., Clin Rheumatol, 2012 32 Halo sign decreases after a mean of
21 days from beginning of therapy
(39)
Contrast-enhanced
ultrasound
Schinkel et al., European Heart Journal
Cardiovascular Imaging, 2013
7 Ultrasonographic contrast allowed better
delineation of carotid arteries lesions. It
also allowed vessel wall
neovascularization in five out of seven
patients (TAK or GCA)
(50)
Transesophageal ultrasound Bezerra Lira-Filho et al., Journal of the
American Society of Echocardiography,
2006
14 71% of thoracic aorta segments were
found to be thickened, and 37% dilated in
the 14 TAK patients studied by
transesophageal echocardiography
(60)
Espinola-Zavaleta et al., Echocardiography
(Mount Kisco, NY). 2005
15 In the studied TAK patient cohort, 67% of
patients had aortic regurgitation, 60%
mitral or tricuspid regurgitation and 33%
reduced coronary reserve measured with
contrast enhancement
(61)
CT angiography Khandelwal et al., European Journal of
Radiology, 2011
15 CT angiography showed variable
thickening of aorta and main branches in
patients with active TAK
(65)
Prieto-Gonzalèz et al., Annals of the
Rheumatic Diseases, 2012
40 CT angiography was able to detect
large-vessel involvement in 67% of
patients with GCA. The proportion was
higher for treatment naïve patients (77%
vs 29%)
(73)
Kang et al., Radiology, 2014 111 53% of patients had coronary artery
involvement, while only 29% were
symptomatic for heart disease
(72)
PET using FDG Besson et al., European Journal of Nuclear
Medicine and Molecular Imaging, 2011
101 Meta-analysis of six studies on patients
with GCA, showing a sensitivity of 80%
and a specificity of 89% for FDG-PET
(81)
Blockmans et al., Arthritis and
Rheumatism, 2006
35 Vascular FDG uptake was shown in 83%
of 35 patients with GCA. It decreased
after 3 months of effective therapy, but no
further decrease was documented at
6 months follow-up
(88)
Fuchs et al., European Journal of Nuclear
Medicine and Molecular Imaging, 2012
30 PET was shown to increase diagnostic
accuracy for LVV from 54 to 71%
(87)
(Continued)
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Table 3 | Continued
Technique Study Number of
patients
Results Reference
PET with PK11195 Pugliese et al., Journal of the American
College of Cardiology, 2010
15 PET/CT allowed visualization of tracer
uptake in the vessels of all the six
patients with active disease, but in none
of the controls
(96)
Magnetic Resonance
Imaging
Mavrogeni, J Am Coll Cardiol, 2004 13 Agreement between bright-blood MRI
angiography and coronary X-ray
angiography in identifying coronary
aneurysms in KD
(106)
Comarmond, Am J Cardiol, 2014 27 Myocardial ischemia detected by LGE at
CMR was>5× greater in patients with
TA compared to matched controls
(133)
Li, J Comput Assist Tomogr, 2011 42 Whole body MRI; wall thickness and
post-contrast signal higher in TAK patients
with active disease
(134)
Koenigkam-Santos, J Clin Rheumatol,
2011
28 GCA/polymyalgia rheumatica; CE-MRA
identified extracranial involvement with
good interobserver agreement
(135)
Mavrogeni, Inflamm Allergy Drug Targets,
2013
28 CMR in Churg–Strauss syndrome showed
cardiac involvement, with worse
prognosis in presence of diffuse
sub-endocardial fibrosis
(136)
FIGURE 1 | Ultrasound imaging of the right carotid artery bifurcation
of a 44-year-old woman with a 10 years history of systemic lupus
erythematosus: the arrows show an atherosclerotic plaque extending
toward the internal carotid artery.
technique allows correct identification of eventual thoracic aorta
and coronary arteries involvement in LVV. Although several
reports of utilization of TEE in the evaluation of LVV, especially in
the setting of perioperative evaluation (57–59), few clinical stud-
ies have been performed using this technique. Bezerra Lira-Filho
and colleagues described the most common lesions in 14 patients
affected by TAK compared with age-matched controls: aortas of
the patients were found to be thicker, more dilated, and stiffer as
compared with controls (60). In another study, Espinola-Zavaleta
et al. assessed coronary reserve in 15 patients with TAK using
contrast-enhanced TEE: 33% of the patients were found to have
reduced coronary reserve, while aortic and mitral valve regurgita-
tion was found in 67% and 60%, respectively (61). CEUS can also
improve the TEE (62).
CT AND CT ANGIOGRAPHY
Computed tomography is well suited to demonstrate patholog-
ical changes in large, deep blood vessels. While it is a widely
available and reproducible technique, it involves the use of ion-
izing radiation and carries a risk connected to the use of iodi-
nated contrast material although radiation dose to the patient has
declined steadily in the past few years due to different techno-
logical advances (63). CT angiography is able to show alterations
both in the wall and in the lumen of affected vessel in LVV (64).
In early vasculitis, concentric mural thickening of the involved
arteries is typically observed (65, 66). On pre-contrast scanning,
the mural thickening has a higher attenuation as compared to
the lumen, while in enhanced images it displays a double ring
enhancement pattern, most evident in the venous phase (67). In
particular, the wall shows a poorly enhanced inner ring and a
more obviously enhanced outer ring; it has been proposed that the
inner ring represents a swollen intima while the outer one repre-
sents active inflammation in the intima and in the media (67, 68).
Mural enhancement usually resolves after successful treatment,
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FIGURE 2 | Ultrasound examination of right proximal common carotid
artery of a patient affected byTakayasu arteritis. B-mode ultrasound (A)
shows long, smooth concentric thickening of the arterial wall.
Contrast-enhanced ultrasound (B) using Optison (GE Healthcare, Little
Chalfont, UK), a contrast media made up of human albumin microbubbles
filled with perflutren, improves definition of the lesion border. Extensive
enhancement can be seen within the vessel wall (arrow). In both panels,
asterisk marks the vessel lumen.
although its improvement may lag behind clinical and laboratory
improvement (69, 70). In advanced disease, CT angiography shows
typical late stage complications such as aneurysms, vessel steno-
sis, or occlusion (66) (Figure 3). Compared with conventional
angiography, CT was able to accurately assess stenotic lesions in
brachiocephalic trunks, carotid arteries, and subclavian arteries
in patients with TAK, with a sensitivity and specificity of 93%
and 98%, respectively (71). In addition, coronary arteries assess-
ment with CT was able to show coronary artery lesions in 53%
of 111 TAK patients, while only 29% had cardiac symptoms (72).
The most common lesions were ostial stenosis, non-ostial stenosis,
and coronary aneurysms. In another study, CT was able to detect
large-vessel involvement in 27 of 40 patients affected by GCA (73).
PET AND PET/CT
Imaging with PET offers unrivaled sensitivity and specificity for
research into tissue perfusion, biochemical pathways, and pharma-
cological mechanisms in vivo. The success of PET is founded on
the properties of positron emitters. Their short physical half-lives
FIGURE 3 | CT angiography [(A) shows axial and (B) sagittal view] of
the aorta of a female patient with advancedTakayasu arteritis who
underwent previous surgical repair of an ascending aorta aneurysm
(*). Several features of the disease are summarized in these images:
post-surgical complications such as pseudoaneurysms at the level of
proximal and distal anastomosis of the vascular graft with the native aorta
(white stars), extensive concentric mural thickening with calcifications of
the aorta (white arrows), and presence of a stent in the main steam with a
calcific stenosis (black arrow).
make it possible to administer a tracer dose high enough to obtain
useful data, but such that the radiation burden to the patient is
acceptably low. A tracer is a measurable substance used to mimic,
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FIGURE 4 | Hybrid PET with PK11195 and CT angiography imaging of an
88-year-old woman presenting with left scalp tenderness, jaw
claudication, and night sweats. The coronal reconstruction (D) and
magnifications of PET (A,E), and contrast-enhanced CT (B,F) and PET/CT
fusion images (C,G) show focal PK11195 uptake in the left temporal artery
above the zygomatic process (solid arrows) compared to the contralateral
artery (open arrows). The arterial target-to-background ratio (TBR) was
higher in the left than in the right temporal artery. On CT angiography, the
left temporal artery lumen (1.8 mm diameter) was irregular with reduced
contrast opacification compared with the contralateral (2.2 mm diameter).
The H&E biopsy specimen (H) of the left temporal artery (4×objective)
shows transmural granulomatous infiltration (containing activated
lymphocytes, macrophages, and multinucleated giant cells), secondary
myofibroblast proliferation, and significant intimal thickening leading to
luminal obliteration. Large part of the media and the internal elastic lamina
are destroyed. The inset (H&E,×100 objective) demonstrates a
multinucleated giant cell. CD68 (macrophage marker, shown in panel I)
staining brown with immunoperoxidase (×4 objective) shows dense
macrophage infiltration with multinucleated cells (inset, ×100 objective).
[adapted with permission from Springer]
follow or trace a chemical compound or process without disturb-
ing the process under study. In the case of PET, this is made possible
by: (1) the high sensitivity of PET imaging which enables the
measurement of radiolabeled tracers administered in picomolar
concentrations, which are sufficiently low so as not to disturb the
processes under study; and (2) the ability of current PET scanners
to perform rapid dynamic imaging and/or list mode acquisitions
that provide good temporal resolution. Although it shows great
sensitivity to even small amounts of probe mass, PET has a rel-
atively poor spatial resolution (23), compared to CT and MRI.
For this reason, coregistration of PET images with contrasted CT
images has been developed, to provide good anatomical localiza-
tion of functional data (74). Using this technique, Gaemperli et al.
first reported detection of temporal artery inflammation using
PET in a patient with GCA (Figure 4) (75).
PET AND PET CT USING FDG
[18F]-fluorodeoxyglucose (FDG) is a radiolabeled glucose analog,
which competes with glucose for transport across the sarcolemma
and phosphorylation by hexokinase and is avidly accumulated by
metabolically active cells. Currently, PET imaging with FDG plays
a major role in the management of cancer patients (76). Acti-
vated inflammatory cells also overexpress glucose transporters
and extract increased amounts of glucose and hence FDG (77).
In large-vessel vasculitides, FDG uptake in the vascular wall is
increased. The uptake is commonly classified on a four-point
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FIGURE 5 | Hybrid CT (A) with PET imaging (B) to identifies [18F]-fluorodeoxyglucose (FDG) accumulation in the vascular wall of abdominal aorta
(arrow) in a female patient withTakayasu arteritis.
visual grading system: no uptake (grade 0), less than liver uptake
(grade 1), uptake similar to that of the liver (grade 2), and uptake
higher than the liver (grade 3) (78). Grades 2 and 3 appear to
be specific for vasculitis (79). Alternatively, the semi-quantitative
aorta to liver ratio proposed by Hautzel et al. provides an excellent
global performance for the diagnosis of GCA, with a sensitivity
of 89% and a specificity of 96%, together as robustness as an
observer-independent method (80). According to a recent meta-
analysis, FDG-PET has a sensitivity of 80% and a specificity of
89% in the diagnosis of GCA, using ACR criteria as reference stan-
dard (81). FDG-PET was also shown to be useful in early diagnosis
of TAK, showing a sensitivity ranging from 65 to 100% and high
specificity (82, 83). Combination of PET with CT imaging was
shown to increase diagnostic yield for LVV, allowing for better
visualization of tracer accumulation in the vascular wall (84, 85)
(see Figure 5 as an example of female patients with inflammation
localized at the abdominal aortic wall identified by accumulation
of FDG) and visualization of small diameter arteries such as tem-
poral artery (86). Diagnostic accuracy of FDG-PET dramatically
decreases after initiation of appropriate therapy (87), providing a
valuable tool for disease monitoring (88, 89). Furthermore, PET
was shown to reliably predict GCA complications, e.g., aortic dila-
tion (90), but it was unable to identify patient at higher risk of
relapse (88). A recent study formally assessed the impact of FDG-
PET on the diagnosis of LVV (87). A panel of international experts
was asked to diagnose and manage patients with suspect LVV either
with or without having access to PET results: PET was shown to
significantly increase diagnostic accuracy from 54 to 71%.
PET/CT USING [11C]-PK11195
[N -methyl-11C]-(R)-1-(2-chlorophenyl)-N -(1-methylpropil)-3-
isoquinoline carboxamide,also known as [11C]-PK11195, is a radi-
olabeled ligand that specifically binds to the translocator protein
(TSPO, 18 kDa), formerly known as peripheral benzodiazepine
receptor (91). TSPO has been shown to be present at high den-
sity in circulating human phagocyte populations, in particular in
monocytes and neutrophils (92). Stimulated human monocytes
further increase TSPO expression, indicating that its overexpres-
sion associates with activation of phagocytes (93). Over the last two
decades, [11C]-PK11195 has been extensively used in a number of
neuroinflammatory and neurodegenerative conditions due to its
high uptake in activated microglia and low uptake in neurons (94).
Subsequent reports have demonstrated [11C]-PK11195 uptake in
synovial macrophages of patients affected by rheumatoid arthritis
(95). Pugliese et al. first applied [11C]-PK11195 in LVV imaging in
a small, proof-of-principle study involving 15 patients, predomi-
nantly affected by TAK and GCA (96). In this study, all five patients
with clinically active vasculitis had markedly increased vascular
uptake of the tracer as compared with patients with quiescent
disease. Standardized uptake values for [11C]-PK11195 correlated
well with quantitative total intra-plaque volumes of distribution,
calculated from dynamic tissue kinetic modeling using a one-
tissue compartment model (97). In one patient, PET/CT images
were obtained after a 20-week course of oral corticosteroids: vas-
cular uptake of [11C]-PK11195 was markedly reduced, and the
reduction was paralleled by clinical improvement and decrease in
biochemical markers of inflammation (96). The estimated effec-
tive dose for CT was 6.0± 0.5 mSv and 2.1± 0.2 mSv for PET scan
and the mean total effective dose was 8.1± 0.6 mSv (96). These
values are comparable to those of a cardiac FDG scan (98). Finally,
[11C]-PK11195 uptake was found to correlate with presence of
inflammatory cells in atherosclerotic plaque specimens obtained
by carotid artery endarterectomy (99). In the same study, carotid
uptake of the radiotracer was higher in patients who had suf-
fered from ischemic stroke, suggesting that this technique may
be useful in detecting unstable high-risk plaque (24, 99). Despite
these promising results, widespread use of [11C]-PK11195 may be
limited by its short physical half-life (20 min), which mandates
an on-site cyclotron facility. New 18F-labeled TSPO ligands, now
undergoing preclinical investigation, may overcome some of these
barriers (100).
MAGNETIC RESONANCE IMAGING
Magnetic resonance imaging is increasingly recognized as a valu-
able tool in the work-up of patients affected by large- and medium-
sized arteries vasculitis (101). MRI has the advantage of avoiding
radiations and nephrotoxic contrast medium, while allowing a
high-resolution characterization of both vessel wall and lumen.
Moreover, systemic vasculitis is increasingly being linked to the
occurrence of heart failure secondary to myocardial damage and
cardiac magnetic resonance (CMR) has proven to be a refined diag-
nostic procedure to evaluate both cardiac function and myocardial
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FIGURE 6 | Aortitis in Behcet’s disease. (A) STIR T2 dark-blood
imaging showing extensive edema of the aortic wall (arrows).
Post-contrast late-enhancement imaging (B) shows extensive
enhancement of the aortic wall (arrows). A typical Takayasu aortitis
presenting with cardiac arrest and acute myocardial infarction in a
16-year-old girl. (C) 3D-MRA reconstructed image, showing dilation of
the ascending aorta and narrowing of the descending aorta.
(D) Post-contrast four-chamber view, showing extensive sub-endocardial
and focally nearly transmural myocardial late enhancement (ischemic
late-enhancement pattern) of the apical and lateral left ventricular walls.
Asterisks highlight the presence of pulmonary edema; the patient was
intubated during the scan.
tissue characterization (102). Avoidance of radiations and tissue
characterization capability render MRI an ideal tool not only in
defining diagnosis and disease extension but also in evaluating
response to treatment and in follow-up. One of the strengths of
MRI is the capability of tissue characterization even in basal con-
ditions, before the administration of contrast, so a typical scan
includes a pre- and a post-contrast phase; in patients in whom a
cardiac examination is also performed, these two steps pertain also
to heart evaluation.
PRE-CONTRAST MRI TECHNIQUES
1. Dark-blood morphologic images (HASTE; T1 or T2 turbo
spin-echo images), acquired in the axial, sagittal, and coronal
planes); in these images blood appears black, while the vessel
wall is clearly depicted and its characteristics, such as thickness
and regularity can be easily ascertained. Short-tau inversion-
recovery images (STIR images) are dark-blood T2-weighted
images in which the signal of fat is saturated and that allow
the identification of tissue edema (103). This sequence is par-
ticularly useful to identify vessel wall active inflammation with
edema in the acute phase and to monitor response to therapy
and disease activity during follow-up (Figure 6A).
2. Bright-blood morphologic images (single-shot true-FISP
images) in which blood appears bright and that allow the
evaluation of vessel wall characteristics.
3. Non-contrast angiography. Time of flight angiography (TOF) is
the most frequently non-contrast angiography used, especially
to study intracranial and peripheral vessels. This technique can
be exploited in patients in whom contrast administration is
contraindicated (104). The presence of slow flow or vessel tor-
tuosity can impair image quality and represent a limitation of
this technique. Bright-blood whole-heart, self-navigated MRI
allowing free-breathing is a technique steadily being improved
to acquire 3D images of the aorta and coronary arteries without
the need of contrast (104, 105). Techniques allowing the eval-
uation of coronary arteries are particularly useful when these
vessels are involved. Mavrogeni et al. demonstrated complete
agreement between bright-blood MRI angiography and coro-
nary X-ray angiography in identifying coronary aneurysms in
patients affected by KD (106). The avoidance of X-ray expo-
sure is particularly advantageous in this young population and
renders MRI the ideal tool for follow-up. Moreover, adding a
complete cardiac evaluation with CMR allows a comprehensive
evaluation of both the coronary tree and heart muscle (107).
POST-CONTRAST MRI TECHNIQUES
Three-dimensional (3D) contrast-enhanced magnetic resonance
angiography (CE-MRA) is the corner stone for vessel lumen
evaluation with high-spatial resolution (Figure 6C). At higher
strength fields (3 T), an improvement in spatial resolution can be
obtained with lower contrast dosage (104). Post-contrast acqui-
sitions include T1-weighted images (e.g., VIBE) targeted at the
evaluation of vessel wall, allowing the identification of thicken-
ing and thrombus stratification and late-enhancement images,
obtained with the inversion-recovery technique, showing contrast
accumulation (the so-called “late enhancement”) in pathologic
vessel walls (Figure 6B).
CARDIAC EVALUATION WITH CMR
Systemic vasculitidies can affect the heart either directly, through
vasculitis-related myocarditis or indirectly, through myocardial
ischemia secondary to coronary artery involvement (102, 108).
CMR allows the evaluation of cardiac volumes and function
through cine images, the assessment of valvular function with
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phase-contrast images and the detection of myocardial edema,
secondary to inflammation or ischemia through STIR T2-images.
Post-contrast images obtained with the inversion-recovery tech-
nique highlight pathologic areas of contrast accumulation in the
myocardium, identifying scar (Figure 6D). CMR is the ideal tool
also to follow-up patients with cardiac involvement, to monitor
response to therapy and disease activity.
IMAGING AND BIOMARKERS
The measurement of acute phase reactant, i.e., C-reactive pro-
tein (CRP) and erythrocyte sedimentation rate (ESR), is currently
recommended for LVV patients follow-up (12) and undoubtedly
provides a useful aid for many patients. However, it is established
that vascular inflammation and disease progression can occur in
the face of normal levels of CRP or ESR, or both (109, 110). In addi-
tion, critical analysis of the utility of CRP and ESR, alongside other
proposed biomarkers of disease activity in TAK, including soluble
adhesion molecules and von Willeband factor, showed that they
do not reliably identify active disease (111). The need for more
effective markers has prompted the evaluation of several differ-
ent new molecules, among which Pentraxin 3 (PTX3) deserves a
special mention. PTX3 is a member of the pentraxin’s superfam-
ily and is induced by different cell types, including endothelial
cells, smooth muscle cells, and mesangial cells upon inflammatory
stimulation (112). Dagna et al. first reported that plasma levels of
PTX3 were higher in patients with active TAK as compared with
patients with inactive disease, and that TAK patients had higher
PTX3 plasma concentration than healthy controls and subjects
suffering from acute infections (113). Subsequent reports showed
high sensitivity and specificity, 82 and 77%, respectively, of PTX3
for the detection of active disease (114, 115), suggesting that it may
be of help in early detection of disease recurrence. Monitoring of
LVVs by means of biomarkers, however, currently appears to be
suboptimal and not fully reliable.
To the best of our knowledge, no systematic study has been per-
formed to assess a correlation between serum level of biomarkers
and imaging findings of inflammation. However, many studies
report a lack of association between serum levels of CRP and ESR
and imaging evidence of active inflammation during follow-up.
In particular, a general trend toward persistence of low-grade pos-
itive imaging after normalization of acute phase reactants after
initiation of treatment is shown for ultrasound (34, 116), FDG-
PET (88) and MRI (117). Furthermore, a study performed with
PK11195-PET showed that this imaging modality was more effec-
tive in identifying clinically active LVV than evaluation of ESR
and CRP (96). While none of these findings appears to be con-
clusive, it is arguable that imaging may be more effective than
currently available routine serological biomarkers in the assess-
ment of LVV activity, and may provide an effective means of
identifying subclinical active disease.
CONCLUSIVE CLINICAL REMARKS
Clinical evaluation still plays a major role in the diagnosis of
LVV, also considering the fact that classification criteria have not
yet been revised in response to the increased sensitivity of non-
invasive imaging techniques (5). The likelihood of early diagnosis,
which would be desirable in order to prevent irreversible vascular
damage, is not facilitated by the protean manifestation of the dis-
eases, and by the lack of constitutional symptoms in up to 50% of
patients (118, 119). The index of suspicion should be held high
for patients with unexplained acute phase response, hyperten-
sion, or symptoms of ischemia, and should trigger the request
for non-invasive imaging (2, 5, 12). Although an early report
questioned its utility in the evaluation of LVV (120), imaging of
superficial vessels by color Doppler ultrasound was subsequently
shown to have a good sensitivity and specificity for the diagnosis
of these diseases (31, 32). Changes in ultrasonographic findings
have been reported after initiation of an effective therapy (38–
40, 121): alongside low economical and biological cost, this makes
color Doppler ultrasound a suitable technique for patients’ follow-
up. CEUS may further enhance diagnostic power and role in the
follow-up of the disease, but evidence is still lacking to warrant
its use in clinical practice. For those patients in whom ultra-
sound examination is negative, PET scanning with FDG is the
logical second-line approach. This technique has been shown to
greatly increase diagnostic accuracy for LVV (87), and may be
particularly useful for those patients with atypical presentation,
in which LVV is only one of the several possibilities (122, 123).
Although FDG uptake decreases with the initiation of an effective
therapy, it is not unusual to detect persistent low-grade uptake
in the involved arteries of patients who have normal acute phase
reactants (124), which may be due to the persistent inflamma-
tory infiltrates that can be detected in surgical specimens from
patients with quiescent disease (110). This fact currently limits
the utility of PET in patients’ follow-up. These shortcomings have
led investigators to explore new ligands for detection of vascu-
lar inflammation, such as [11C]-PK11195, which has not been
extensively validated yet, but for which promising preliminary
result exist (96). MRI imaging can represent an alternative second-
line examination, allowing complete evaluation of the aorta and
its branches, but appropriate visualization of blood vessel lumen
and wall necessitates of dedicated protocols not widely available
(125, 126). In addition, MRI allows thorough evaluation of the
heart, which is frequently involved, albeit sometimes silently, in
LVV. The lack of ionizing radiation makes it suitable for repeti-
tion in patients follow-up. CT imaging has similar indications to
MRI for what concerns blood vessels examination, and is more
widely available. It may have a role in the evaluation of coro-
nary arteries involvement in these patients. However, it involves
the use of ionizing radiations and nephrotoxic iodinated contrast,
which questions its safety for repeated exams in the follow-up
of the patients. Current guidelines, while supporting the use of
non-invasive imaging in the diagnosis and management of LVV
(12), do not give systematic indications its use, deferring the selec-
tion of the approach to the practicing physician preferences and
local expertize. The use of ultrasonography is well established in
the diagnosis of GCA: while a positive ultrasound finding does
not replace temporal artery biopsy for the diagnosis, it may pro-
vide the definite diagnosis for biopsy negative patients with a
strong clinical suspicion for cephalic vessel GCA (127). Ultra-
sound may thus be the first imaging approach in such patients.
FDG-PET, especially if combined with anatomical CT imaging,
appears to be particularly appropriate subsequently, as it allows
to detect lesions throughout the entire arterial tree (128). PET
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FIGURE 7 | Proposed guidelines-based algorithm for imaging evaluation
of patients with large-vessel vasculitis. GCA: giant cell arteritis; TAK:
Takayasu arteritis; TAB: temporal artery biopsy. *Atypical presentations for
GCA include main large-vessel involvement or fever of unknown origin. MRI is
a suitable approach only for the former presentation. Currently, no “gold
standard” imaging is defined for TAK.
imaging may be particularly appropriate for patients affected by
GCA (127) in whom large-vessel involvement and systemic symp-
toms, e.g., limb claudication, predominate, and in patients with
atypical presentation, i.e., fever of unknown origin (122). MRI
may have similar indications, although less established. In the
subsequent management of the patient, imaging of the arter-
ial tree is recommended every 2 years in order to monitor for
lesion progression: echocardiogram for early detection of proxi-
mal aortic aneurysm, PET or MRI may be included (127, 129). For
what concerns TAK, guideline indications are even less precise.
A thorough assessment of the arterial tree is currently recom-
mended upon diagnosis, and MRI, PET, and CT are well suited
for this purpose (128), while none of these techniques appear to
provide a “gold standard” (130). The use of ultrasound is not
well established in this disease (131), but it may provide the tool
for non-invasive assessment of cephalic vessel, especially carotid
artery. The detection of the “halo sign” may provide information
on disease activity. One of the major challenges in therapeutic
management of TAK is in fact recurrence: even with effective
corticosteroid therapy, up to 72% of the patients experience multi-
ple recurrences within 6 months (119). While no routine imaging
follow-up is currently recommended for early detection of recur-
rence, FDG-PET may be the imaging technique of choice upon
clinical suspicion due to its strong correlation with disease activ-
ity (132). Diagrams in Figure 7 summarize the suggested imaging
approach.
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